News
ABCL
4.430
+6.75%
0.280
AbCellera Biologics Among 3 Promising Penny Stocks
Simply Wall St · 1d ago
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), AbCellera Biologics (ABCL) and Pulmonx (LUNG)
TipRanks · 2d ago
AbCellera Biologics announces annual shareholder meeting notice
PUBT · 2d ago
Weekly Report: what happened at ABCL last week (0420-0424)?
Weekly Report · 5d ago
A Look At AbCellera Biologics (ABCL) Valuation After Its Planned ABCL635 Phase 1 Data Update
Simply Wall St · 04/23 18:14
AbCellera: Strategic Pivot to an Internal Pipeline and Key ABCL635 Readouts Position Shares for Multibillion-Dollar Upside
TipRanks · 04/23 13:15
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL) and Fennec Pharmaceuticals (FENC)
TipRanks · 04/22 14:50
AbCellera target is profile more attractive than Vistagen, says JonesResearch
TipRanks · 04/22 14:45
AbCellera Biologics (ABCL) Is Up 6.8% After Announcing First Human Data Timeline For ABCL635
Simply Wall St · 04/21 21:20
Press Release: AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
Dow Jones · 04/20 13:16
AbCellera To Disclose Interim Results From Phase 1 Portion Of Its Study Of ABCL635, Including Observed Safety Profile, Pharmacokinetic, And Pharmacodynamic Target Engagement Data, During Q1 Earnings Call On May 11
Benzinga · 04/20 13:06
AbCellera updates financial calendar with upcoming quarterly earnings call
PUBT · 04/20 13:01
Weekly Report: what happened at ABCL last week (0413-0417)?
Weekly Report · 04/20 09:08
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Telix Pharmaceuticals (OtherTLPPF) and Johnson & Johnson (JNJ)
TipRanks · 04/15 12:21
Weekly Report: what happened at ABCL last week (0406-0410)?
Weekly Report · 04/13 09:09
How Investors Are Reacting To AbCellera Biologics (ABCL) After New Jones Trading Coverage Initiation
Simply Wall St · 04/13 03:25
A Look At AbCellera Biologics (ABCL) Valuation After New Optimistic Coverage From Jones Trading
Simply Wall St · 04/11 02:22
AbCellera Biologics Initiated at Buy by Jones Trading
Dow Jones · 04/10 12:30
AbCellera Biologics Price Target Announced at $11.00/Share by Jones Trading
Dow Jones · 04/10 12:30
Jones Trading Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $11
Benzinga · 04/10 12:20
More
Webull provides a variety of real-time ABCL stock news. You can receive the latest news about Abcellera Biologics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.